Potential Cancer Drugs Licensed In Deal Worth Up To $137M
A pharmaceutical company said Monday it has entered a cash, stock and royalty deal potentially worth about $137 million to license treatments under development, one of which is intended to treat...To view the full article, register now.
Already a subscriber? Click here to view full article